Cannabinoid Receptor Activation on Haematopoietic Cells and Enterocytes Protects against Colitis
Posted on July 22, 2022
Cannabinoid receptor [CB] activation can attenuate inflammatory bowel disease [IBD] in experimental models and human cohorts. However, the roles of the microbiome, metabolome, and the respective contributions of haematopoietic and non-haematopoietic cells in the anti-colitic effects of cannabinoids have yet to be determined.